Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Transgenic Group's share price for the quarter that ended in Mar. 2026 was 円256. Transgenic Group's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 17 Mil. Therefore, Transgenic Group's market cap for the quarter that ended in Mar. 2026 was 円4,263 Mil.
Transgenic Group's quarterly market cap
increased
from Mar. 2025 (円3,047 Mil) to Sep. 2025 (円3,597 Mil) and
increased
from Sep. 2025 (円3,597 Mil) to Mar. 2026 (円4,263 Mil).
Transgenic Group's annual market cap
declined
from Mar. 2024 (円4,016 Mil) to Mar. 2025 (円3,047 Mil) but then
increased
from Mar. 2025 (円3,047 Mil) to Mar. 2026 (円4,263 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Transgenic Group's Enterprise Value for Today is 円3,611 Mil.
Transgenic Group (TSE:2342) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Transgenic Group Market Cap Related Terms
Transgenic Group Market Cap Historical Data
* Premium members only.
The historical data trend for Transgenic Group's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:2342 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Transgenic Group's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Transgenic Group Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Transgenic Group's Market Cap distribution charts can be found below:
* The bar in red indicates where Transgenic Group's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Transgenic Group's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Transgenic Group (TSE:2342) has a Market Cap of 円3,597 Mil as of Jul. 05, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Transgenic Group and its competitors. According to the industry distribution chart, Transgenic Group ranks #1066 out of 1422 companies in the Biotechnology industry, placing it in the top 75%.
Is Transgenic Group's Market Cap too high?
Transgenic Group's current Market Cap is 円3,597 Mil. Based on the distribution chart, Transgenic Group ranks #1066 out of 1422 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Transgenic Group has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Transgenic Group's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Transgenic Group ranks #1066 out of 1422 companies for Market Cap. This places Transgenic Group in the lower half of its industry. The industry median Market Cap is 121.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 121.26, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Transgenic Group and its competitors. For the Biotechnology industry, the median Market Cap is 121.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Transgenic Group's current Market Cap is 円3,597 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transgenic Group stock overvalued right now?
Based on GuruFocus' analysis, Transgenic Group (TSE:2342) is currently considered Modestly Undervalued. The stock's GF Value™ is 円257.46, compared to a current price of 円216.00 — trading 16.1% below its estimated fair value. The current Market Cap is 円3,597 Mil. Transgenic Group's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Transgenic Group (TSE:2342), the current Market Cap is 円3,597 Mil as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Transgenic Group (TSE:2342) Overvalued in 2026?
Based on GuruFocus' analysis, Transgenic Group stock appears to be undervalued.
The current stock price of 円216.00 is trading 16.1% below its estimated GF Value™ of 円257.46.
GuruFocus considers Transgenic Group to be Modestly Undervalued.
Key valuation signals for TSE:2342:
Market Cap: 円3,597 Mil
GF Value™: 円257.46 vs. price of 円216.00 (16.1% below fair value)
No single metric tells the full story. See the TSE:2342 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Transgenic Group Inc formerly Trans Genic Inc is engaged in offering assistance of non-clinical experiments using large animals and general rearing management work, and non-clinical trial service using large animals. The company has two segments: Drug discovery support business, and Investment and consulting business.
60GF Score
Get the complete analysis for TSE:2342
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2342 has been successfully added to your 
